Citations

Mayo Clinic

Showing 10 of 108602 citations.

Prostate Cancer: Advances in Genetic Testing and Clinical Implications
Abdelrazek, Ahmad , Ghoniem, Khaled, Ahmed, Mohamed E. , Joshi, Vidhu B. , Mahmoud, Ahmed , Saeed, Nader, Khater, Nazih , ElSharkawy, Mohammed Said , Gamal, Ahmed , Kwon, Eugene D., Kendi, A. Tuba , Kendi, A Tuba , Joshi, Vidhu B , Mahmoud, Ahmed M , Ahmed, Mohamed

Uro | March 24, 2023 | Volume: 3 | Issue: 2 | Pages: 91-103

10.3390/uro3020012 Get It

The demand for genetic testing (GT) for prostate cancer (PCa) is expanding, but there is limited knowledge about the genetic counseling (GC) needs of men. A strong-to-moderate inherited genetic predisposition causes approximately 5–20% of prostate cancer (PCa). In men with prostate cancer, germline testing may benefit the patient by informing treatment options, and if a mutation is noticed, it may also guide screening for other cancers and have family implications for cascade genetic testing (testing of close relatives for the same germline mutation). Relatives with the same germline mutations may be eligible for early cancer detection strategies and preventive measures. Cascade family testing can be favorable for family members, but it is currently unutilized, and strategies to overcome obstacles like knowledge deficiency, family communication, lack of access to genetic services, and testing expenses are needed. In this review, we will look at the genetic factors that have been linked to prostate cancer, as well as the role of genetic counseling and testing in the early detection of advanced prostate cancer.
The Liver and Glycogen: In Sickness and in Health
Soon, Gwyneth Shook Ting , Soon, Gwyneth S T , Torbenson, Michael

International Journal of Molecular Sciences | March 24, 2023 | Volume: 24 | Issue: 7 | Pages: 6133

10.3390/ijms24076133 | PMID 37047105 Get It

The liver is a major store of glycogen and is essential in maintaining systemic glucose homeostasis. In healthy individuals, glycogen synthesis and breakdown in the liver are tightly regulated. Abnormal glycogen metabolism results in prominent pathological changes in the liver, often manifesting as hepatic glycogenosis or glycogen inclusions. This can occur in genetic glycogen storage disease or acquired conditions with insulin dysregulation such as diabetes mellitus and non-alcoholic fatty liver disease or medication effects. Some primary hepatic tumors such as clear cell hepatocellular carcinoma also demonstrate excessive glycogen accumulation. This review provides an overview of the pathological manifestations and molecular mechanisms of liver diseases associated with abnormal glycogen accumulation.
Comparison of Migraine Characteristics in Patients With and Without Inflammatory Bowel Disease: A Retrospective Cohort Study
Sileno, Sean, Bi, Yan , Dorenkott, Sean M., Omer, Mohamed , Salih, Ahmed, Ghoz, Hassan , Valery, Jose R. , Harris, Dana M. , Rozen, Todd D. , White, Launia J. , Sileno, Sean M, Ghoz, Hassan M, Stancampiano, Fernando F , Valery, Jose , Harris, Dana M , Heckman, Michael G. , Stancampiano, Fernando F.

Journal of Primary Care & Community Health | March 24, 2023 | Volume: 14 | Issue: No issue available | Pages: No page available

10.1177/21501319231164307 | PMID 36960555 Get It

Background: Survey studies have found an increased prevalence of migraine in patients with inflammatory bowel disease (IBD). However, the clinical characteristics of migraines in this population are unknown. We conducted a retrospective medical record review study to characterize migraines in the IBD population. Methods: Six hundred seventy-five migraine patients (280 with IBD, 395 without IBD) who were evaluated at Mayo Clinic Rochester, Mayo Clinic Arizona, or Mayo Clinic Florida between July 2009 and March 2021 were included. Patients with ICD codes for migraine and either Crohn’s disease (CD) or ulcerative colitis (UC) were selected. Electronic health care records were reviewed. Patients confirmed to have IBD and migraine were included. Demographic, IBD, and migraine characteristics were collected. Statistical analysis was completed using SAS. Results: Patients with IBD were less often male (8.6% vs 21.3%, P < .001) and had a higher Charlson Comorbidity Index (>2: 24.6% vs 15.7%, P = .003); 54.6% had CD and 39.3% had UC. Patients with IBD had migraine with aura and without aura more frequently ( OR 2.20, P < .001 and OR 2.79, P < .001, respectively) than non-IBD patients. Additionally, those with IBD less commonly had chronic migraine (OR 0.23, P < .001) and less commonly had chronic migraine or treatment for migraine (ORs 0.23-0.55, P ≤ .002). Conclusions: Migraine with and without aura have increased prevalence in IBD patients. Further study of this topic will be helpful to clarify the prevalence of migraine, establish this population’s response to treatment, and better understand the reason(s) for a low rate of treatment.
Mindfulness Using a Wearable Brain Sensing Device for Health Care Professionals During a Pandemic: A Pilot Program
Ghosh, Karthik, Nanda, S. , Schroeder, Darrell R. , Bauer, Brent A. , Fokken, Shawn C. , Ganesh, Ravindra , Hanson, Jennifer L., Lindeen, Stephanie A. , Pruthi, Sandhya , Croghan, Ivana T. , Hurt, Ryan T. , Ganesh, Ravindra , Lindeen, Stephanie A , Croghan, Ivana T , Schroeder, Darrell , West, Colin P. , Fischer, Karen M.

Journal of Primary Care & Community Health | March 24, 2023 | Volume: 14 | Issue: No issue available | Pages: No page available

10.1177/21501319231162308 | PMID 36960553 Get It

Objective: The purpose of this feasibility pilot study was to evaluate safety and adherence of a wearable brain sensing wellness device designed to reduce stress among healthcare professionals (HCP). Methods: A total of 40 HCP were invited to participate in an open-label pilot study. Participants were asked to use a brain sensing wearable device (MUSE-S™) on a daily basis to reduce their stress, for a total of 90 days. Total study participation duration was 180 days. Study enrollment began in August 2021 and ended December 2021. The exploratory outcomes included stress, depression, sleep, burn-out, resilience, quality of life, and cognition. Results: Among the 40 HCP in study, the majority were female (85%), white (87.5%) and with an average age of 41.3 ± 11.0 years (SD). Participants used the wearable device an average of 23.8 times over a 30-day period with a mean duration of 5.8 min with each use. Study results demonstrate the positive impact of guided mindfulness using the wearable device MUSE-S™ and its accompanying application (APP). A statistically significant improvement was found for a reduction in stress ( P < .001) and improvement in resilience ( P = .02), quality of life ( P = .003), and cognition ( P < .001). The majority (91.9%) of the participants indicated they felt more relaxed after using the device, and 73% indicated they would continue to use this device at end-of-study. No adverse effects were reported. Conclusion: Study results show that 3 to 10 min of guided meditation during work hours through the use of a brain sensing wearable device is safe and acceptable, with associated health benefits for HCP.
Characteristics of pediatric patients with multiple sclerosis and related disorders infected with SARS-CoV-2
Schreiner, Teri , Wilson-Murphy, Molly , Mendelt-Tillema, Jan, Waltz, Michael , Codden, Rachel , Gorman, Mark , Krupp, Lauren , Lotze, Tim, Mar, Soe , Ness, Jayne , Roalstad, Shelly, Rose, John , Shukla, Nikita , Wheeler, Yolanda , Casper, T. Charles , Krupp, Lauren , Rensel, Mary R. , Chitnis, Tanuja , Schreiner, Teri , Shukla, Nikita Malani , Benson, Leslie, Goyal, Manu S. , Rodriguez, Moses , Waubant, Emmanuelle L.

Multiple Sclerosis Journal | March 24, 2023 | Volume: 29 | Issue: 4-5 | Pages: 576-584

10.1177/13524585231151948 | PMID 36960480 Get It

Background: Pediatric patients with multiple sclerosis (POMS) and related disorders, clinically isolated syndrome (CIS), myelin oligodendrocyte glycoprotein antibody disorder (MOGAD), and neuromyelitis optica spectrum disorder (NMOSD), are commonly treated with immunosuppressants. Understanding the impact of SARS-CoV-2 infection in patients may inform treatment decisions. Objective: Characterize SARS-CoV-2 infection prevalence and severity among a cohort of patients with POMS and related disorders, as well as the impact of disease-modifying therapies (DMTs). Methods: POMS and related disorders patients enrolled in a large, prospective registry were screened for COVID-19 during standard-of-care neurology visits. If confirmed positive of having infection, further analysis was undertaken. Results: Six hundred and sixty-nine patients were surveyed between March 2020 and August 2021. There were 73 confirmed COVID-19 infections. Eight of nine hospitalized patients (89%), and all patients admitted to the ICU were treated with B cell depleting therapy. The unadjusted odds ratio of hospitalization among those who tested positive of having had COVID-19 was 15.27 among those on B-cell-depleting therapy ( p = 0.016). Conclusions: B-cell-depleting treatment was associated with a higher risk of COVID-19, higher rates of hospitalization, and ICU admission, suggesting this therapy carries a higher risk of severe infection in POMS and related disorders.
Mechanical extraction of a pulmonary valve vegetation in a patient with endocarditis
Senapati, Sidhartha G, Sabbah, Michael S. , Pislaru, Sorin V. , Motiei, Arashk

European Heart Journal - Cardiovascular Imaging | March 23, 2023 | Volume: 24 | Issue: 7 | Pages: e110-e110

10.1093/ehjci/jead054 | PMID 37086035 Get It

Antibody-mediated interferences affecting cardiac troponin assays: recommendations from the IFCC Committee on Clinical Applications of Cardiac Biomarkers
Hammarsten, Ola , Warner, Janet , Lam, Leo , Kavsak, Peter A. , Aakre, Kristin M. , Collinson, Paul , Jaffe, Allan S. , Saenger, Amy K., Mills, Nicholas L. , Omland, Torbjørn , Ordóñez‐Llanos, Jordi , Apple, Fred S. , Aakre, Kristin M , Collinson, Paul O , Mills, Nicholas L , Lindahl, Bertil , Jaffe, Allan S. , Body, Richard , Kavsak, Peter

Clinical Chemistry and Laboratory Medicine (CCLM) | March 23, 2023 | Volume: 61 | Issue: 8 | Pages: 1411-1419

10.1515/cclm-2023-0028 | PMID 36952681 Get It

Abstract The International Federation of Clinical Chemistry Committee on Clinical Applications of Cardiac Biomarkers (IFCC C-CB) provides educational documents to facilitate the interpretation and use of cardiac biomarkers in clinical laboratories and practice. Our aim is to improve the understanding of certain key analytical and clinical aspects of cardiac biomarkers and how these may interplay. Measurements of cardiac troponin (cTn) have a prominent place in the clinical work-up of patients with suspected acute coronary syndrome. It is therefore important that clinical laboratories know how to recognize and assess analytical issues. Two emerging analytical issues resulting in falsely high cTn concentrations, often several fold higher than the upper reference limit (URL), are antibody-mediated assay interference due to long-lived cTn-antibody complexes, called macrotroponin, and crosslinking antibodies that are frequently referred to as heterophilic antibodies. We provide an overview of antibody-mediated cTn assay interference and provide recommendations on how to confirm the interference and interpret the results.
An Improved Method for Estimating Nephron Number and the Association of Resulting Nephron Number Estimates with Chronic Kidney Disease Outcomes
Đenić, Aleksandar , Alexander, Mariam P., Wilson, Luke D., Augustine, Joshua J. , Luehrs, Anthony C. , Stegall, Mark D. , Kline, Timothy L. , Sharma, Vidit , Thompson, R. Houston, Alexander, Mariam P. , Alexander, Mariam P , Stegall, Mark D , Rule, Andrew D , Denic, Aleksandar , Mullan, Aidan F. , Augustine, Joshua , Rule, Andrew D.

Journal of the American Society of Nephrology | March 23, 2023 | Volume: 34 | Issue: 7 | Pages: 1264-1278

10.1681/asn.0000000000000124 | PMID 36958059 Get It

Significance Statement Nephron number currently can be estimated only from glomerular density on a kidney biopsy combined with cortical volume from kidney imaging. Because of measurement biases, refinement of this approach and validation across different patient populations have been needed. The prognostic importance of nephron number also has been unclear. The authors present an improved method of estimating nephron number that corrects for several biases, resulting in a 27% higher nephron number estimate for donor kidneys compared with a prior method. After accounting for comorbidities, the new nephron number estimate does not differ between kidney donors and kidney patients with tumor and shows consistent associations with clinical characteristics across these two populations. The findings also indicate that low nephron number predicts CKD independent of biopsy and clinical characteristics in both populations. Background Nephron number can be estimated from glomerular density and cortical volume. However, because of measurement biases, this approach needs refinement, comparison between disparate populations, and evaluation as a predictor of CKD outcomes. Methods We studied 3020 living kidney donors and 1354 patients who underwent radical nephrectomy for tumor. We determined cortex volume of the retained kidney from presurgical imaging and glomerular density by morphometric analysis of needle core biopsy of the donated kidney and wedge sections of the removed kidney. Glomerular density was corrected for missing glomerular tufts, absence of the kidney capsule, and then tissue shrinkage on the basis of analysis of 30 autopsy kidneys. We used logistic regression (in donors) and Cox proportional hazard models (in patients with tumor) to assess the risk of CKD outcomes associated with nephron number. Results Donors had 1.17 million nephrons per kidney; patients with tumor had 0.99 million nephrons per kidney. A lower nephron number was associated with older age, female sex, shorter height, hypertension, family history of ESKD, lower GFR, and proteinuria. After adjusting for these characteristics, nephron number did not differ between donors and patients with tumor. Low nephron number (defined by <5th or <10th percentile by age and sex in a healthy subset) in both populations predicted future risk of CKD outcomes independent of biopsy and clinical characteristics. Conclusions Compared with an older method for estimating nephron number, a new method that addresses several sources of bias results in nephron number estimates that are 27% higher in donors and 1% higher in patients with tumor and shows consistency between two populations. Low nephron number independently predicts CKD in both populations. Podcast This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/JASN/2023_06_22_JASN0000000000000124.mp3
Hemosuccus Pancreaticus: Diagnostic Pitfalls of a Rare Condition
Busebee, Bradley , AT, Kurdi, BR, Stultz, LN, Sayegh, Busebee, Brad , Kurdi, Ahmed T. , Stultz, Benjamin R. , Sayegh, Lea N. , Coelho–Prabhu, Nayantara

ACG Case Reports Journal | March 23, 2023 | Volume: 10 | Issue: 3 | Pages: e01014

10.14309/crj.0000000000001014 | PMID 36998341 Get It

ABSTRACT The combination of cirrhosis and chronic pancreatitis is rare and poses increased risk of hemorrhage requiring close clinical monitoring. We present a patient with history of alcohol-associated cirrhosis and chronic pancreatitis who was admitted to the intensive care unit with clinical hemorrhage believed secondary to epistaxis. After initial delay, esophagogastroduodenoscopy ultimately found blood and clots evacuating through the ampulla consistent with hemosuccus pancreaticus confirmed with computed tomography angiography. The patient ultimately improved with coil and gel foam vascular embolization. This case highlights the dangers of early diagnostic closure and presents a rare finding of hemosuccus without pseudoaneurysm formation.
Interventional vs surgical procedures in localized/nonmetastatic insulinomas (ablation vs surgery)
Sada, Alaa , McKenzie, Travis J. , Vella, Adrian, Levy, Michael J. , Hálfdánarson, Þorvarður R. , Halfdanarson, Thorvardur R , Levy, Michael J.

Endocrine-Related Cancer | March 23, 2023 | Volume: 30 | Issue: 6 | Pages: No page available

10.1530/erc-22-0362 | PMID 36952635 Get It

Localized insulinoma is an uncommon entity that can result in substantial morbidity due to the associated hypoglycemia. Recent studies have suggested an increase in the incidence of insulinoma in recent decades that may possibly be secondary to increased awareness, incidental diagnoses, and better diagnostic methods. Diagnosing and localizing insulinoma within the pancreas can be challenging, but advances in nuclear imaging may improve diagnostic accuracy. Delays in diagnosis are common, but once a localized insulinoma is diagnosed and appropriately treated, the long-term prognosis is excellent. Surgical resection is considered the standard of care management option for localized insulinoma, but tumor ablation with endoscopic ultrasound guidance has also been shown to be an effective and safe method for therapy.